Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma.

Thomas Witzig1, Lubomir Sokò2, Eric Jacobsen3, Ranjana Advani4, Rufino Mondejar5, Miguel Piris6, Francis Burrows7, Carrie Melvin7, Vishnu Mishra7, Catherine Scholz7 and Antonio Gualberto1

1Mayo Clinic, Rochester, MN, USA; 2H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3Dana-Farber Cancer Institute, Boston, MA USA; 4Stanford University Medical Center, Stanford, CA, USA, 5IDIVAL Instituto de Investigación Marqués de Valdecilla, Santander, Spain, 6Fundación Jiménez Díaz, Madrid, Spain, 7Kura Oncology, Inc., La Jolla, CA, USA

INTRODUCTION
Tipifarnib:
• Potent and highly selective inhibitor of Farnesyl Transferase
• Previously studied in > 5,000 patients (pts)
• Previous trials without genetic selection yielded insufficient clinical activity to support registration, though evidence of single agent activity had been reported.
• Manageable safety profile as single agent therapy (<25% treatment discontinuation).

OBJECTIVES
• This is a Phase 2 study designed to investigate the antitumor activity of tipifarnib in 18 pts with relapsed or refractory PTCL.
• Primary Objective: ORR by IWC and/or mSWAT
• Secondary Objectives: PFS, DOR, safety/tolerability
• Exploratory Objectives: Biomarkers

METHODS
Study Design
• Tipifarnib 600 mg orally twice daily on Days 1 – 7 and 15 – 21 in 28-day cycles
• Simon 2-stage design for ORR
• Stage 1: Need 2 CR/PRs in first 11 pts
• Stage 2: If Stage 1 criteria met, enroll 7 pts
• For 10% (H0) vs 30% (H1) ORR, targeting ≥ 4 CR/PRs out of 18

Key Eligibility Criteria
• Diagnosis of PTCL including:
  • Anaplastic large cell lymphoma (ALCL), ALK positive
  • ALCL, ALK negative
  • Enteropathy-associated T-cell lymphoma (AITL)
  • Enteropathy-related AITL
  • Extramedullary T-cell lymphoma, nasal type
  • Hematopoietic T-cell lymphoma
  • PTCL, no otherwise specified (NOS)
  • Subcutaneous panniculitis-like T-cell lymphoma
  • Relapsed or refractory to at least 1 prior systemic cytotoxic therapy.

AITL Expansion Cohort:
• Based on observed antitumor activity in stages 1 and 2, an AITL expansion cohort (N = 12) is currently enrolling.

RESULTS
N = 18
<table>
<thead>
<tr>
<th>Gender</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>4 (22)</td>
</tr>
<tr>
<td>Male</td>
<td>14 (78)</td>
</tr>
<tr>
<td>PTCL Subtype</td>
<td></td>
</tr>
<tr>
<td>AITL</td>
<td>2 (11)</td>
</tr>
<tr>
<td>ALCL, ALK negative</td>
<td>1 (6)</td>
</tr>
<tr>
<td>PTCL, NOS</td>
<td>15 (83)</td>
</tr>
<tr>
<td>Number of prior therapies, median (range)</td>
<td>4 (1 – 7)</td>
</tr>
</tbody>
</table>

Toxicities
• Toxicities were consistent with known safety profile of tipifarnib. No patient discontinued due to AEs.
• Grade ≥ 3 TEAEs occurring in > 10% of pts were hematology-related and included neutropenia (83%), thrombocytopenia (61%), leukopenia (50%), anemia (39%), febrile neutropenia (33%) and lymphopenia (17%).
• Myelosuppression was manageable with treatment interruption, dose reductions and/or growth factor support.
• Starting dose was reduced from 900 mg to 600 mg based on the observed tolerability profile in stage 1.

CONCLUSIONS
• These preliminary data indicate that tipifarnib has antitumor activity, particularly in pts with AITL histology, with high levels of CXCL12 gene expression and absence of 3’UTR CXCL12 gene variation.

Tipifarnib was generally well-tolerated. Most common treatment-related AEs (grade ≥ 3) were myelosuppression, including neutropenia, thrombocytopenia and leukopenia.

The phase 2 study has been extended to enroll an additional 12 pts with AITL aimed at confirming the preliminary observations and validating CXCL12 as a biomarker of tipifarnib activity.

REFERENCES
4. Tian F, et. al. Stem Cells Int. 2015;2015:63230

Corresponding author: catherine@kuraoncology.com